生物技术
业务
人类健康
风险分析(工程)
生化工程
生物
医学
环境卫生
工程类
作者
Eric Banan‐Mwine Daliri,Byong H. Lee,Deog Hwan Oh
标识
DOI:10.1080/10408398.2017.1319795
摘要
The remarkable growth of therapeutic peptide development in the past decade has led to a large number of market approvals and the market value is expected to hit $25 billion by 2018. This significant market increase is driven by the increasing incidences of metabolic and cardiovascular diseases and technological advancements in peptide synthesis. For this reason, the search for bioactive peptides has also increased exponentially. Many bioactive peptides from food and nonfood sources have shown positive health effects yet, obstacles such as the need to implement efficient and cost-effective strategies for industrial scale production, good manufacturing practices as well as well-designed clinical trials to provide robust evidence for supporting health claims continue to exist. Several other factors such as the possibility of allergenicity, toxicity and the stability of biological functions of the peptides during gastrointestinal digestion would need to be addressed.
科研通智能强力驱动
Strongly Powered by AbleSci AI